Skip to main content

Table 6 Treatment-emergent adverse events (≥5 % in any group), safety population: noncarrier study

From: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

Event PBO + BAP 0.5 (n = 39) BAP 0.5 + BAP 0.5 (n = 66) PBO + BAP 1.0 (n = 37) BAP 1.0 + BAP 1.0 (n = 56)
ARIA-E (vasogenic cerebral edema) 3 (7.7) 2 (3.0) 6 (16.2) 3 (5.4)
Urinary tract infection 2 (5.1) 7 (10.6) 1 (2.7) 0
Headache 1 (2.6) 1 (1.5) 3 (8.1) 2 (3.6)
Gastroenteritis 0 0 3 (8.1) 0
Nasopharyngitis 3 (7.7) 1 (1.5) 1 (2.7) 2 (3.6)
Delusion 3 (7.7) 3 (4.5) 0 0
Gait disturbance 3 (7.7) 0 1 (2.7) 0
Fall 0 3 (4.5) 2 (5.4) 4 (7.1)
Dizziness 1 (2.6) 4 (6.1) 0 0
Cerebral microhemorrhage 0 1 (1.5) 0 3 (5.4)
Cognitive disorder 1 (2.6) 2 (3.0) 2 (5.4) 3 (5.4)
Depression 0 0 2 (5.4) 0
Subdural hematoma 0 0 0 3 (5.4)
Aggression 2 (5.1) 0 0 0
Anemia 2 (5.1) 1 (1.5) 0 0
Cough 2 (5.1) 0 0 2 (3.6)
Nausea 2 (5.1) 0 0 0
  1. Data presented as n (%)
  2. ARIA-E amyloid-related imaging abnormalities with edema or effusions, BAP bapineuzumab, PBO placebo